Dextran conjugates in drug delivery

Expert Opinion on Drug Delivery

Volumn 9, Issue 5, 2012, Pages 509-523

  Varshosaz, Jaleh ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

anticancer drug; biopolymer; conjugation; copolymer; dextran; drug delivery; micelles; prodrug

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BETA INTERFERON; BUDESONIDE; CYCLOSPORIN A; DEOXYCHOLIC ACID; DEXAMETHASONE; DEXTRAN; DEXTRAN DERIVATIVE; DRUG CARRIER; FLURBIPROFEN; IMIDAZOLE DERIVATIVE; KETOPROFEN; KETOROLAC; NANOMATERIAL; NONSTEROID ANTIINFLAMMATORY AGENT; PERIODATE; POLYMER; SUPERPARAMAGNETIC IRON OXIDE;

CHEMICAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SOLUBILITY; DRUG TARGETING; ESTERIFICATION; HUMAN; HYDROGEL; HYPERTHERMIC THERAPY; MOLECULAR WEIGHT; OXIDATION; REVIEW; SOLID TUMOR; SUBRETINAL NEOVASCULARIZATION;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; DEXTRANS; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; ESTERIFICATION; HUMANS; HYDROGELS; HYPERTHERMIA, INDUCED; LIVER DISEASES; MICELLES; MOLECULAR STRUCTURE; NANOSTRUCTURES; NEOPLASMS; PRODRUGS; SOLUBILITY; STOMACH ULCER;

EID: 84859944275     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.673580     Document Type: Review

References (101)

1. Suflet DM, Chitanu GC, Desbrieres J. Phosphorylated polysaccharides.
2. Synthesis and properties of phosphorylated dextran. Carbohydr Polym 2010;82(4):1271-7
3. Purama RK, Goswami P, Khan AT, Goyal A. Structural analysis and properties of dextran produced by Leuconostoc mesenteroides NRRL B-640. Carbohydr Polym 2009;76(1):30-5
4. Can HK, Denizli BK, Guner A, Rzaev ZMO. Effect of functional crosslinking agents on preparation and swelling properties of dextran hydrogels. Carbohydr Polym 2005;59(1):51-6
5. Harboe E, Johansen M, Larsen C. Macromolecular pro-drugs. VI. Coupling of naproxen to dextrans and in vitro characterization of the conjugates. Farm Sci Ed 1988;16:73-85
6. Lukyanov AN, Sawant RM, Hartner WC, Torchilin VP. PEGylated dextran as long-circulating pharmaceutical carrier. J Biomater Sci Polym Ed 2004;15(5):621-30 (Pubitemid 38832585)
7. Williams AS, Taylor G. Synthesis, characterization and release of cromoglycate from dextran conjugates. Int J Pharm 1982;83(1-3):233-9
8. Weiner BZ, Tahan M, Zilkha A. Polymers containing phenethylamines. J Med Chem 1972;15:410-13
9. Bocher M, Boldicke T, Kie- M, Bilitewski U. Synthesis of mono- and bifunctional peptide-dextran conjugates for the immobilization of peptide antigens on ELISA plates: Properties and application. J Immun Methods 1997;208(2):191-202 (Pubitemid 28015346)
10. Axen R, Porath J, Ernback S. Chemical coupling of peptides and proteins to polysaccharides by means of cyanogens halides. Nature 1967;214:1302-4
11. Lapasin R, Pricl S. Rheology of Industrial Polysaccharides: Theory and Applications. Aspen Publication; New York: 1995
12. Edman P, Ekman B, Sjoholm I. Immobilization of proteins in microspheres of biodegradable polyacyldextran. J Pharm Sci 1980;69(7):838-42 (Pubitemid 11237870)
13. Brondsted H, Anderson C, Hovgaard L. Crosslinked dextran-A new capsule material for colon targeting of drugs. J Control Release 1998;53(1-3):7-13 (Pubitemid 28218685)
14. Dogan AK, Gumusderelioglu M, Aksoz E. Controlled release of EGF and bFGF from dextran hydrogels in vitro and in vivo. J Biomed Mater Res B Appl Biomater 2005;74(1):504-10 (Pubitemid 40917722)
15. Kim SH, Won CY, Chu CC. Synthesis and characterization of dextran based hydrogels prepared by photocrosslinking. Carbohydr Polym 1999;40(3):183-90 (Pubitemid 129587859)
16. Kim SH, Won CY, Chu CC. Synthesis and characterization of dextran-maleic acid based hydrogel. J Biomed Mater Res 1999;46(2):160-70
17. Zhang Y, Chu CC. Biodegradable dextran-polylactide hydrogel networks: Their swelling, morphology and the controlled release of indomethacin. J Biomed Mater Res 2002;59(2):318-28 (Pubitemid 33126637)
18. Bartkowiak A, Jezierska I, Spychai T. An EPR study of polysaccharide copper (II) complexes in composite dextran/epichlorohydrin gels. Polym Bull 1998;41(2):199-206 (Pubitemid 128486905)
19. Jin R, Moreira Teixeira LS, Dijkstra PJ, et al. Enzymatically crosslinked dextran-tyramine hydrogels as injectable scaffolds for cartilage tissue engineering. Tissue Eng Part A 2010;16(8):2429-40
20. Jin R, Hiemstra C, Zhong Z, Feijen J. Enzyme-mediated fast in situ formation of hydrogels from dextran-tyramine conjugates. Biomater 2007;28(18):2791-800 (Pubitemid 46482659)
21. Feeney M, Giannuzzo M, Paolicelli P, Casadei MA. Hydrogels of dextran containing nonsteroidal anti-inflammatory drugs as pendant agents. Drug Deliv 2007;14(2):87-93
22. Porfire AS, Zabaleta V, Gamazo C, et al. Influence of dextran on the bioadhesive properties of poly(anhydride) nanoparticles. Int J Pharm 2010;390(1):37-44
23. Jeong YI, Kim DH, Chung CW, et al. Doxorubicin-incorporated polymeric micelles composed of dextran-b-poly (DL-lactide-co-glycolide) copolymer. Int J Nanomed 2011;6:1415-27
24. Bang JY, Song CE, Kim C, et al. Cytotoxicity of amphotericin B-incorporated polymeric micelles composed of poly(DL-lactide-coglycolide)/ dextran graft copolymer. Arch Pharm Res 2008;31(11):1463-9
25. Du YZ, Weng Q, Yuan H, Hu FQ. Synthesis and antitumor activity of stearate-g-dextran micelles for intracellular doxorubicin delivery. ACS Nano 2010;4(11):6894-902
26. Afifi H, da Silva MA, Nouvel C, et al. Associative networks of cholesterol-modified dextran with short and long micelles. Soft Matter 2011;7:4888-99
27. Sun H, Guo B, Li X, et al. Shell-sheddable micelles based on dextran-ss-poly(epsilon-caprolactone) diblock copolymer for efficient intracellular release of doxorubicin. Biomacromolecules 2010;11(4):848-54
28. QiaoYing W, HongYing S, ChunChao X, et al. Amphiphilic dextran/magnetite nanocomposites as magnetic resonance imaging probes. Chin Sci Bull 2009;54(17):2925-33
29. Zhang YL, Dou XW, Jin T. Synthesis and self-Assembly behavior of amphiphilic diblock copolymer dextran-block-poly(epsilon-caprolactone) (DEX-b-PCL) in aqueous media. eXPRESS Polymer Letters 2010;4(10):599-610
30. Qiu F, Feng J, Wu DQ, et al. Nanosized micelles self-Assembled from amphiphilic dextran graft methoxypolyethylene glycol/poly(epsilon-caprolactone) copolymers. Eur Polym J 2009;45(4):1024-31
31. Jeong YI, Chung KD, Choi KC. Doxorubicin release from self-Assembled nanoparticles of deoxycholic acid-conjugated dextran. Arch Pharm Res 2011;34(1):159-67
32. Varshosaz J, Hassanzadeh F, Sadeghi H, et al. Synthesis and characterization of folate-targeted micellar nanocapsules of dextran/retinoic acid. Proceed 2nd Int Conf Nanotechnol: Fundamentals and Applications; 28 - 29 July 2011; Ottawa, Ontario, Canada
33. Varshosaz J. Hassanzadeh F. Sadeghi H. et al. Folate-targeted micellar nanocapsules of dextran/retinoic acid for doxorubicin delivery in acute leukemia Proceed 4th Int. Conf Nanostructures ICNS4); 12 - 14 March 2012; Kish Island, I.R. Iran
34. Mu M, Pan X, Yao P, Jiang M. Acidic solution properties of beta-casein-graft-dextran copolymer prepared through Maillard reaction. J Colloid Interface Sci 2006;301(1):98-106 (Pubitemid 44092754)
35. Etzel MR, Bund T. Monoliths for the purification of whey protein-dextran conjugates. J Chromatogr A 2011;1218(17):2445-50
36. Mehvar R. Recent trends in the use of polysaccharides for improved delivery of therapeutic agents: Pharmacokinetic and pharmacodynamic perspectives. Curr Pharm Biotechnol 2003;4(5):283-302 (Pubitemid 37220861)
37. Moore A, Marecos E, Bogdanov A Jr, Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 2000;214(2):568-74 (Pubitemid 30077721)
38. Fujita T, Yasuda Y, Takakura Y, et al. Tissue distribution of 111In-labeled uricase conjugated with charged dextrans and polyethylene glycol. J Pharmacobiodyn 1991;14(11):623-9
39. Mumtaz S, Bachhawat BK. Conjugation of proteins and enzymes with hydrophilic polymers and their applications. Indian J Biochem Biophys 1991;28(5-6):346-51
40. Zhao Q, Tolmachev V, Carlsson J, et al. Effects of dextranation on the pharmacokinetics of short peptides. A PET study on mEGF. Bioconjug Chem 1999;10(6):938-46
41. Jiang D, Salem AK. Optimized dextran-polyethylenimine conjugates are efficient non-viral vectors with reduced cytotoxicity when used in serum containing environments. Int J Pharm 2011;[Epub ahead of print] doi:10.1016/j.ijpharm.2011.10.032
42. Goodwin AP, Tabakman SM, Welsher K, et al. Phospholipid-dextran with a single coupling point: A useful amphiphile for functionalization of nanomaterials. J Am Chem Soc 2009;131(1):289-96
43. Kopp AF, Laniado M, Dammann F, et al. MR imaging of the liver with resovist: Safety, efficacy, and pharmacodynamic properties. Radiologia 1997;204(3):749-56 (Pubitemid 27369036)
44. Kobeiter H, Georgiades CS, Leakakos T, et al. Targeted transarterial therapy of Vx-2 rabbit liver tumor with Yttrium-90 labeled ferromagnetic particles using an external magnetic field. Anticancer Res 2007;27(2):755-60 (Pubitemid 46586978)
45. Jordan A, Wust P, Fahling H, et al. Inductive heating of ferrimagnetic particles and magnetic fluids: Physical evaluation of their potential for hyperthermia. Int J Hyperthermia 1993;9(1):51-68 (Pubitemid 23052367)
46. Moroz P, Jones SK, Winter J, et al. Targeting liver tumors with hyperthermia: Ferromagnetic embolization in a rabbit liver tumor model. J Surg Oncol 2001;78(1):22-49
47. Moroz P, Metcalf C, Gray BN. Histologic analysis of liver tissue following hepatic arterial infusion of ferromagnetic particles in a rabbit tumour model. Biomater 2003;16(3):455-64 (Pubitemid 36356777)
48. Motoyama J, Yamashita N, Morino T, et al. Hyperthermic treatment of DMBA-induced rat mammary cancer using magnetic nanoparticles. Biomagn Res Technol 2008;6(2):1-6
49. Takamatsu S, Matsui O, Gabata T, et al. Selective induction hyperthermia following transcatheter arterial embolization with a mixture of nano-sized magnetic particles (ferucarbotran) and embolic materials: Feasibility study in rabbits. Radiat Med 2008;26(4):179-87 (Pubitemid 351754720)
50. Wada S, Yue L, Tazawa K, et al. New local hyperthermia using dextran magnetite complex (DM) for oral cavity: Experimental study in normal hamster tongue. Oral Dis 2001;7(3):192-5 (Pubitemid 32538943)
51. Mitsumori M, Hiraoka M, Shibata T, et al. Development of intra-Arterial hyperthermia using a dextran-magnetite complex. Int J Hyperthermia 1994;10(6):785-93 (Pubitemid 24352986)
52. Mitsumori M, Hiraoka M, Shibata T, et al. Targeted hyperthermia using dextran magnetite complex: A new treatment modality for liver tumors. Hepatogastroenterology 1996;43(12):1431-7 (Pubitemid 27007328)
53. Sonoda A, Nitta N, Ohta S, et al. Development of a conjugated gadolinium and cisplatin-gelatin possessing properties as an intravascular contrast agent for MR imaging. Eur J Radiol 2009;71(3):570-5
54. Konishi M, Tabata Y, Kariya M, et al. In vivo anti-tumor effect of dual release of cisplatin and adriamycin from biodegradable gelatin hydrogel. J Control Release 2005;103(1):7-19 (Pubitemid 40248557)
55. Hilger I, Hergt R, Kaiser WA. Use of magnetic nanoparticle heating in the treatment of breast cancer. IEE Proc Nanobiotechnol 2005;152(1):33-9 (Pubitemid 40453794)
56. Sonoda A, Nitta N, Nitta-Seko A, et al. Complex comprised of dextran magnetite and conjugated cisplatin exhibiting selective hyperthermic and controlled-release potential. Int J Nanomed 2010;5:499-504
57. Zhang J, Misra RD. Magnetic drug-targeting carrier encapsulated with thermosensitive smart polymer: Core-shell nanoparticle carrier and drug release response. Acta Biomater 2007;3(6):838-50 (Pubitemid 47382675)
58. Varshosaz J, Ahmadi F, Emami J, et al. Microencapsulation of budesonide with dextran by spray drying technique for colon-targeted delivery: An in vitro/in vivo evaluation in induced colitis in rat. J Microencapsul 2011;28(1):62-73
59. Ahmadi F, Varshosaz J, Emami J, et al. Preparation and in vitro/in vivo evaluation of dextran matrix tablets of budesonide in experimental ulcerative colitis in rats. Drug Deliv 2011;18(2):122-30
60. Varshosaz J, Ahmadi F, Emami J, et al. Colon delivery of budesonide using solid dispersion in dextran for the treatment and secondary prevention of ulcerative colitis in rat. Int J Prev Med 2010;1(2):115-23
61. Varshosaz J, Emami J, Tavakoli N, et al. Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis. Int J Pharm 2009;365(1-2):69-76
62. Varshosaz J, Emami J, Fassihi A, et al. Effectiveness of budesonide-succinate-dextran conjugate as a novel prodrug of budesonide against acetic acid-induced colitis in rats. Int J Colorectal Dis 2010;25(10):1159-65
63. Varshosaz J, Emami J, Ahmadi F, et al. Preparation of budesonide-dextran conjugates using glutarate spacer as a colon-targeted drug delivery system: In vitro/in vivo evaluation in induced ulcerative colitis. J Drug Target 2011;19(2):140-53
64. Pang YN, Zhang Y, Zhang ZR. Synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting. World J Gastroenterol 2002;8(5):913-17
65. Zhou SY, Mei QB, Liu L, et al. Characteristics of drug-release in vitro of different dextran-dexamethasone conjugates. Yao Xue Xue Bao 2003;38(5):388-91
66. Larsen C, Jensen BH, Olesen HP. Bioavailability of ketoprofen from orally administered ketoprofen-dextran ester prodrugs in the pig. Acta Pharm Nord 1991;3(2):71-6
67. Shrivastava PK, Shrivastava SK. Dextran carrier macromolecule for colon specific delivery of celecoxib. Curr Drug Deliv 2010;7(2):144-51
68. Ahmad S, Tester RF, Corbett A, Karkalas J. Dextran and 5-Aminosalicylic acid (5-ASA) conjugates: Synthesis, characterisation and enzymic hydrolysis. Carbohydr Res 2006;341(16):2694-701 (Pubitemid 44572199)
69. Lee Y, Kim IH, Kim J, et al. Evaluation of dextran-flufenamic acid ester as a polymeric colon-specific prodrug of flufenamic acid, an anti-inflammatory drug, for chronotherapy. J Drug Target 2011;19(5):336-43
70. Vyas S, Trivedi P, Chaturvedi SC. Ketorolac-dextran conjugates: Synthesis, in vitro and in vivo evaluation. Acta Pharm 2007;57(4):441-50
71. Shrivastava SK, Jain DK, Trivedi P. Dextrans-potential polymeric drug carriers for flurbiprofen. Pharmazie 2003;58(6):389-91 (Pubitemid 36733846)
72. Giannuzzo M, Corrente F. Feeney M, et al. pH-Sensitive hydrogels of dextran: Synthesis, characterization and in vivo studies. J Drug Target 2008;16(9):649-59
73. Francis MF, Lavoie L, Winnik FM, Leroux JC. Solubilization of cyclosporin A in dextran-g-polyethyleneglycolalkyl ether polymeric micelles. Eur J Pharm. Biopharm. 2003;56(3):337-46 (Pubitemid 37346506)
74. Tu J, Zhong S, Li P. Studies on acyclovir-dextran conjugate: Synthesis and pharmacokinetics. Drug Dev Ind Pharm 2004;30(9):959-65 (Pubitemid 39453047)
75. Nakamura J, Nakajima N, Matsumura K, Hyon SH. Water-soluble taxol conjugates with dextran and targets tumor cells by folic acid immobilization. Anticancer Res 2010;30(3):903-9
76. Bisht S, Maitra A. Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy. Nanomed Nanobiotechnol 2009;1(4):415-25
77. Mitra S, Gaur U, Ghosh PC, Maitra AN. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release 2001;74(1-3):317-23 (Pubitemid 32727639)
78. Zhang J, Luo M, Zhou Y, Zhang JR. Anti-human IgG-dextran-Adriamycin conjugate for immunotargeting of S180 sarcoma: Effects on the tumor weight and survival time of the tumor-bearing mice. Nan Fang Yi Ke Da Xue Xue Bao 2008;28(4):646-8
79. Dang W, Colvin HB, Saltzman WM. Covalent coupling of methotrexate to dextran enhances the penetration of cytotoxicity into a tissue-like matrix. Cancer Res 1994;54(7):1729-35 (Pubitemid 24116177)
80. Nomura T, Saikawa A, Morita S, et al. Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran conjugates after intratumoural injection. J Control Release 1998;52(3):239-52 (Pubitemid 28135253)
81. Hao AJ, Deng YJ, Suo XB, Cao YH. Synthesis and characteristics of the fluorouracil-dextran conjugates. Pharmazie 2006;61(5):489-90 (Pubitemid 43724432)
82. Nakashima M, Ichinose K, Kanematsu T, et al. In vitro characteristics and in vivo plasma disposition of cisplatin conjugated with oxidized and dicarboxymethylated dextrans. Biol Pharm Bull 1999;22(7):756-61 (Pubitemid 29361717)
83. Lam W, Leung CH, Chan HL, Fong WF. Toxicity and DNA binding of dextran-doxorubicin conjugates in multidrug-resistant KB-V1 cells: Optimization of dextran size. Anticancer Drugs 2000;11(5):377-84 (Pubitemid 30459473)
84. Guu JA, Hsiue GH, Juang TM. Synthesis and biological properties of antitumor-Active conjugates of ADR with dextran. J Biomater Sci Polym Ed 2002;13(10):1135-51
85. Mehvar R, Robinson MA, Reynolds JM. Molecular weight dependent tissue accumulation of dextrans: In vivo studies in rats. J Pharm Sci 1994;83(10):1495-9
86. Penugonda S, Agarwal HK, Parang K, Mehvar R. Plasma pharmacokinetics and tissue disposition of novel dextran-methylprednisolone conjugates with peptide linkers in rats. J Pharm Sci 2010;99(3):1626-37
87. Melton RG, Wiblin CN, Baskerville A, et al. Covalent linkage of carboxypeptidase G2 to soluble dextrans-II. In vivo distribution and fate of conjugates. Biochem Pharmacol 1987;36(1):113-21 (Pubitemid 17010671)
88. Melton RG, Wiblin CN, Foster RL, Sherwood RF. Covalent linkage of carboxypeptidase G2 to soluble dextrans-I. Properties of conjugates and effects on plasma persistence in mice. Biochem Pharmacol 1987;36(1):105-12 (Pubitemid 17227219)
89. Kaneo Y, Fujihara Y, Tanaka T, et al. Intrahepatic delivery of glutathione by conjugation to dextran. Pharm Res 1989;6(12):1025-31 (Pubitemid 20094224)
90. Takakura Y, Fujita T, Hashida M, Sezaki H. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm Res 1990;7:339-46 (Pubitemid 20266586)
91. Nishida K, Tonegawa C, Nakane S, et al. Effect of electric charge on the hepatic uptake of macromolecules in the rat liver. Int J Pharm 1990;65:7-17
92. Nishida K, Mihara K, Takino T, et al. Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver. Pharm Res 1991;8:437-44
93. Lake JR, Licko V, Van Dyke RW, Scharschmidt BF. Biliary secretion of fluid-phase markers by the isolated perfused rat liver. Role of transcellular vesicular transport. J Clin Invest 1985;76:676-84 (Pubitemid 15023122)
94. Vansteenkiste S, Schacht E, Duncan R, et al. Fate of glycosylated dextrans after in vivo administration. J Control Release 1991;16:91-100
95. Nishikawa M, Kamijo A, Fujita T, et al. Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting. Pharm Res 1993;10(9):1253-61 (Pubitemid 23261822)
96. Schechter B, Chen L, Arnon R, Wilchek M. Organ selective delivery using a tissue-directed sreptavidin-biotin system: Targeting 5-fluorouridine via TNP-streptavidin. J Drug Target 1999;6(5):337-48 (Pubitemid 29237590)
97. Nishikawa M, Yamashita F, Takakura Y, et al. Demonstration of the receptor-mediated hepatic uptake of dextran in mice. J Pharm Pharmacol 1992;44(5):396-401
98. De Carvalho PB, Ramos DCC, Cotrim PC, Ferreira EI. Synthesis and in vitro evaluation of potential anti-leishmanial targeted drugs of pyrimethamine. J Pharm Sci 2003;92(10):2109-16 (Pubitemid 37175641)
99. Yasukawa T, Kimura H, Tabata Y, et al. Targeting of interferon to choroidal neovascularization by use of dextran and metal coordination. Invest Ophthalmol Vis Sci 2002;43(3):842-8 (Pubitemid 34184505)
100. Roseeuw E, Coessens V, Balazuc AM, et al. Degradation, and antimicrobial properties of targeted macromolecular prodrugs of norfloxacin. Antimicrob Agents Chemother 2003;47(11):3435-41 (Pubitemid 37345701)
101. Danhauser-Riedl S, Hausmann E, Schick HD, et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs 1993;11(2-3):187-95 (Pubitemid 23277239)